We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

600623:SSEShanghai Huayi Group Corporation Ltd. Class A Analysis

Data as of 2026-05-29 - not real-time

CN¥8.74

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Shanghai Huayi Group trades at CNY 8.74, sitting below its 20‑day (9.70) and 50‑day (9.85) SMAs and marginally under the 200‑day SMA (8.92), indicating a short‑term technical weakness. The RSI of 35 and a bearish MACD histogram reinforce a modest oversold condition, while volume is on a downtrend and the 30‑day volatility spikes above 50%, suggesting heightened price swings. On the fundamentals side, the stock appears inexpensive relative to book (P/B 0.82) and its DCF‑derived fair value of CNY 11.40, yet it commands a steep trailing PE of 32.4 and delivers thin profit margins (1.2% net) and a low ROE (~1.9%). The balance sheet is solid with CNY 16.46 bn cash versus CNY 12.56 bn debt, and free cash flow remains positive, supporting a 2.05% dividend yield at a 66% payout ratio.
Overall, the company sits in a low‑beta (≈0.34) chemical sector, offering a modest dividend and a cash‑rich profile, but faces sector‑specific cyclical and regulatory headwinds. The market sentiment is extremely greedy (Fear‑Greed Index 93), which, combined with the technical downside and high volatility, suggests caution in the near term despite the valuation upside.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below short‑term SMAs and bearish MACD
  • High 30‑day volatility
  • Support level at CNY 8.52 provides downside buffer

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value (CNY 11.40) exceeds market price
  • Strong cash position and positive free cash flow
  • Attractive dividend yield with sustainable payout

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Low beta indicating defensive profile
  • Undervalued relative to book and intrinsic value
  • Stable dividend and solid balance sheet supporting long‑run returns

Key Metrics & Analysis

Financial Health

Revenue Growth1.60%
Profit Margin1.22%
P/E Ratio32.4
ROE1.92%
ROA0.03%
Debt/Equity40.58
P/B Ratio0.8
Op. Cash FlowCN¥6.5B
Free Cash FlowCN¥1.4B

Technical Analysis

TrendNeutral
RSI35.3
SupportCN¥8.52
ResistanceCN¥11.07
MA 20CN¥9.70
MA 50CN¥9.85
MA 200CN¥8.92
MACDBearish
VolumeDecreasing
Fear & Greed Index93.21

Valuation

Fair ValueCN¥11.40
GradeUndervalued
TypeBlend
Dividend Yield2.05%

Risk Assessment

Beta0.34
Volatility50.13%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.